{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:59:55Z","timestamp":1784383195880,"version":"3.55.0"},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,12,7]]},"DOI":"10.1248\/bpb.b24-00485","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T22:11:54Z","timestamp":1733523114000},"page":"2021-2027","source":"Crossref","is-referenced-by-count":1,"title":["Optimal Blood Sampling Time for Area under the Concentration\u2013Time Curve Estimation of Vancomycin by Assessing the Accuracy of Four Bayesian Software"],"prefix":"10.1248","volume":"47","author":[{"given":"Takaaki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences"},{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Motoki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> infections in adults and children. <i>Clin. Infect. Dis.<\/i>, <b>52<\/b>, e18\u2013e55 (2011).","DOI":"10.1093\/cid\/ciq146"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro B. Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus<\/i> infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Am. J. Health Syst. Pharm.<\/i>, <b>77<\/b>, 835\u2013864 (2020).","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, Hamada Y, Kimura T, Mayumi T, Ueda T, Nakajima K, Takesue Y. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>Pharmaceutics<\/i>, <b>14<\/b>, 489 (2022).","DOI":"10.3390\/pharmaceutics14030489"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Bradley N, Lee Y, Sadeia M. Assessment of the implementation of AUC dosing and monitoring practices with vancomycin at hospitals across the United States. <i>J. Pharm. Pract.<\/i>, <b>35<\/b>, 864\u2013869 (2022).","DOI":"10.1177\/08971900211012395"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Oda K, Hashiguchi Y, Kimura T, Tsuji Y, Shoji K, Takahashi Y, Matsumoto K, Kawamura H, Saito H, Takesue Y. Performance of area under the concentration\u2013time curve estimations of vancomycin with limited sampling by a newly developed web application. <i>Pharm. Res.<\/i>, <b>38<\/b>, 637\u2013646 (2021).","DOI":"10.1007\/s11095-021-03030-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Donagher J, Martin JH, Barras MA. Individualised medicine: why we need Bayesian dosing. <i>Intern. Med. J.<\/i>, <b>47<\/b>, 593\u2013600 (2017).","DOI":"10.1111\/imj.13412"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Turner RB, Kojiro K, Shephard EA, Won R, Chang E, Chan D, Elbarbry F. Review and validation of Bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. <i>Pharmacotherapy<\/i>, <b>38<\/b>, 1174\u20131183 (2018).","DOI":"10.1002\/phar.2191"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Shingde RV, Reuter SE, Graham GG, Carland JE, Williams KM, Day RO, Stocker SL. Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure. <i>J. Antimicrob. Chemother.<\/i>, <b>75<\/b>, 3293\u20133302 (2020).","DOI":"10.1093\/jac\/dkaa320"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? <i>Antimicrob. Agents Chemother.<\/i>, <b>58<\/b>, 309\u2013316 (2014).","DOI":"10.1128\/AAC.01653-13"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Carreno JJ, Lomaestro B, Tietjan J, Lodise TP. Pilot study of a Bayesian approach to estimate vancomycin exposure in obese patients with limited pharmacokinetic sampling. <i>Antimicrob. Agents Chemother.<\/i>, <b>61<\/b>, e02478-16 (2017).","DOI":"10.1128\/AAC.02478-16"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Pai MP, Hong J, Krop L. Peak measurement for vancomycin AUC estimation in obese adults improves precision and lowers bias. <i>Antimicrob. Agents Chemother.<\/i>, <b>61<\/b>, e02490-16 (2017).","DOI":"10.1128\/AAC.02490-16"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Oda K, Yamada T, Matsumoto K, Hanai Y, Ueda T, Samura M, Shigemi A, Jono H, Saito H, Kimura T. Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration\u2013time curve: a simulation study. <i>Clin. Transl. Sci.<\/i>, <b>16<\/b>, 2265\u20132275 (2023).","DOI":"10.1111\/cts.13626"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E. Prospective trial on the use of trough concentration <i>versus<\/i> area under the curve to determine therapeutic vancomycin dosing. <i>Antimicrob. Agents Chemother.<\/i>, <b>62<\/b>, e02042-17 (2018).","DOI":"10.1128\/AAC.02042-17"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese adult patients. <i>Ther. Drug Monit.<\/i>, <b>20<\/b>, 139\u2013148 (1998).","DOI":"10.1097\/00007691-199804000-00003"},{"key":"15","unstructured":"15) Nakashima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for infection. <i>Chemotherapy<\/i>, <b>40<\/b>, 210\u2013214 (1992)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. <i>Clin. Infect. Dis.<\/i>, <b>42<\/b> (Suppl. 1), S35\u2013S39 (2006).","DOI":"10.1086\/491712"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Rodvold KA, Pryka RD, Garrison M, Rotschafer JC. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. <i>Ther. Drug Monit.<\/i>, <b>11<\/b>, 269\u2013275 (1989).","DOI":"10.1097\/00007691-198905000-00009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. <i>J. Clin. Pharm. Ther.<\/i>, <b>34<\/b>, 473\u2013483 (2009).","DOI":"10.1111\/j.1365-2710.2008.01016.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Matzke GR, Mcgory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. <i>Antimicrob. Agents Chemother.<\/i>, <b>25<\/b>, 433\u2013437 (1984).","DOI":"10.1128\/AAC.25.4.433"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. <i>J. Pharmacokinet. Biopharm.<\/i>, <b>9<\/b>, 503\u2013512 (1981).","DOI":"10.1007\/BF01060893"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. <i>Clin. Pharmacol. Ther.<\/i>, <b>26<\/b>, 294\u2013305 (1979).","DOI":"10.1002\/cpt1979263294"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. <i>Bone Marrow Transplant.<\/i>, <b>48<\/b>, 452\u2013458 (2013).","DOI":"10.1038\/bmt.2012.244"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kufel WD, Seabury RW, Mogle BT, Beccari MV, Probst LA, Steele JM. Readiness to implement vancomycin monitoring based on area under the concentration\u2013time curve: A cross-sectional survey of a national health consortium. <i>Am. J. Health Syst. Pharm.<\/i>, <b>76<\/b>, 889\u2013894 (2019).","DOI":"10.1093\/ajhp\/zxz070"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. <i>Ther. Drug Monit.<\/i>, <b>16<\/b>, 513\u2013518 (1994).","DOI":"10.1097\/00007691-199410000-00013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Katip W, Jaruratanasirikul S, Pattharachayakul S, Wongpoowarak W, Jitsurong A, Lucksiri A. The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock. <i>Infect. Drug Resist.<\/i>, <b>9<\/b>, 253\u2013260 (2016).","DOI":"10.2147\/IDR.S121513"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, Tricot S, Alfandari S. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia. <i>Med. Mal. Infect.<\/i>, <b>41<\/b>, 652\u2013656 (2011).","DOI":"10.1016\/j.medmal.2011.09.014"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/12\/47_b24-00485\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T03:38:39Z","timestamp":1734752319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/12\/47_b24-00485\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00485","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]},"article-number":"b24-00485"}}